Lupin Ltd Stock Price Today (NSE: LUPIN)
Fundamental Score
Lupin Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lupin Ltd share price today is ₹2415.00, down 0.26% on NSE/BSE as of 31 July 2026. Lupin Ltd (LUPIN) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.14L (Cr). The 52-week high for LUPIN share price is ₹2526.90 and the 52-week low is ₹1836.80. At a P/E ratio of 20.04x, LUPIN is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 28.68% and a debt-to-equity ratio of 0.29.
Lupin Ltd Share Price Chart — NSE/BSE Historical Performance
Lupin Ltd share price chart: 0.73% return over the past month. 52-week high ₹2526.90, 52-week low ₹1836.80.
Lupin Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2428.40 | ₹2435.00 | ₹2404.00 | ₹2415.00 | 10.06L (Cr) | |
| ₹2455.00 | ₹2474.80 | ₹2416.00 | ₹2421.20 | 10.70L (Cr) | |
| ₹2405.00 | ₹2463.00 | ₹2402.00 | ₹2447.00 | 11.39L (Cr) | |
| ₹2409.20 | ₹2416.80 | ₹2383.30 | ₹2395.80 | 6.08L (Cr) | |
| ₹2371.00 | ₹2432.10 | ₹2368.10 | ₹2410.00 | 11.79L (Cr) | |
| ₹2360.00 | ₹2388.40 | ₹2340.00 | ₹2370.50 | 7.25L (Cr) | |
| ₹2484.00 | ₹2523.70 | ₹2476.10 | ₹2514.80 | 7.82L (Cr) | |
| ₹2431.20 | ₹2494.80 | ₹2424.00 | ₹2478.50 | 6.89L (Cr) | |
| ₹2480.70 | ₹2489.60 | ₹2428.00 | ₹2443.20 | 6.78L (Cr) | |
| ₹2487.96 | ₹2511.29 | ₹2478.43 | ₹2482.50 | 6.26L (Cr) |
Lupin Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2428.00 | ₹2526.90 | ₹2340.00 | ₹2415.00 | -0.54% | |
| ₹2285.40 | ₹2440.80 | ₹2219.80 | ₹2419.00 | +5.85% | |
| ₹2320.00 | ₹2494.00 | ₹2210.60 | ₹2267.70 | -2.25% | |
| ₹2346.00 | ₹2381.00 | ₹2232.80 | ₹2305.20 | -1.74% | |
| ₹2275.60 | ₹2377.60 | ₹2241.60 | ₹2313.90 | +1.68% | |
| ₹2135.30 | ₹2336.30 | ₹2078.20 | ₹2301.90 | +7.80% | |
| ₹2114.00 | ₹2226.30 | ₹2073.60 | ₹2152.80 | +1.84% | |
| ₹2094.90 | ₹2146.90 | ₹2036.70 | ₹2109.50 | +0.70% | |
| ₹1967.00 | ₹2091.40 | ₹1944.10 | ₹2082.20 | +5.86% | |
| ₹1917.40 | ₹2006.10 | ₹1900.00 | ₹1963.50 | +2.40% | |
| ₹1887.10 | ₹2062.80 | ₹1875.00 | ₹1911.30 | +1.28% | |
| ₹1883.90 | ₹2009.80 | ₹1836.80 | ₹1894.90 | +0.58% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lupin Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lupin Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LUPIN across key market metrics for learning purposes.
Positive Indicators
14 factors identified
Strong Return on Equity (28.68%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (29.93%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 20.04 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (101.49%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (31.89%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.02% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (36.81% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (37.02% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.87x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹9511.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 47.02%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Lupin Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lupin Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lupin LtdLupin Ltd...Selected✓ LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹425.70₹426 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Lupin Ltd PE Ratio History
Historical price-to-earnings ratio for LUPIN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹71.69 | ₹2109.50 | 29.4x |
| FY 2024 | ₹41.87 | ₹2355.70 | 56.3x |
| FY 2023 | ₹9.41 | ₹1322.95 | 140.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lupin Ltd Dividend History
Annual cash dividends paid by LUPIN — dividend yield 0.72%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹365.31 Cr |
| FY 2024 | ₹182.80 Cr |
| FY 2023 | ₹182.50 Cr |
| FY 2022 | ₹295.09 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Lupin Ltd Quarterly Performance
Latest quarterly metrics for LUPIN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
31.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
101.49%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.02%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
37.02%
Compounded annual net profit growth over 5 years
Lupin Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LUPIN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lupin Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Lupin Ltd (LUPIN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Lupin Ltd
About LUPIN (Lupin Ltd)
Lupin Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing healthcare accessibility worldwide. From its origins as a manuf...acturer of tuberculosis drugs, the company has broadened its scope considerably, now encompassing a diverse portfolio that spans complex generics, branded formulations, biosimilars, and active pharmaceutical ingredients (APIs). Lupin distinguishes itself through its intensive research and development efforts, focusing on creating novel therapeutic solutions and improving existing treatments across key therapeutic areas. The company's sophisticated manufacturing infrastructure, strategically located across the globe, ensures consistent quality and efficient production to meet the demands of a global market. With a strong emphasis on patient-centricity, Lupin continues to forge partnerships and invest in cutting-edge technologies to address unmet medical needs. Lupin's robust presence in the global pharmaceutical arena is underscored by its strategic market penetration. The company has cultivated significant operations in major markets, including North America, India, and Europe, while also strategically expanding into emerging economies. This geographical diversification reduces risk and provides access to a broader patient base. Lupin's commercial strategy emphasizes the delivery of high-value products and services that improve patient outcomes. By maintaining strong relationships with healthcare professionals, payers, and other stakeholders, Lupin ensures its products are readily available and appropriately utilized. This comprehensive approach contributes to the company's sustained growth and enduring reputation in the industry. The strength of Lupin lies not only in its tangible assets but also in its unwavering commitment to sustainability and ethical business practices. The company places a high priority on environmental stewardship, actively implementing initiatives to minimize its carbon footprint and promote responsible resource management. Lupin's ethical framework is deeply ingrained in its culture, fostering a responsible and transparent work environment. This commitment to corporate social responsibility extends to the communities in which it operates, as Lupin actively supports healthcare programs and initiatives that improve the quality of life for underserved populations. By integrating sustainability and ethical conduct into its core operations, Lupin ensures its long-term success while making a positive impact on the world.
Company Details
Key Leadership
Corporate Events
LUPIN Share Price: Frequently Asked Questions
What is the current share price of Lupin Ltd?
Lupin Ltd (LUPIN) trades at ₹2415.00 on NSE and BSE. Market cap ₹1.14L (Cr). Educational data only.
What is the P/E ratio of Lupin Ltd?
Lupin Ltd has a P/E of 20.04x vs industry average 34.89x.
What is the Bull Run score for Lupin Ltd?
Lupin Ltd has a Bull Run score of 83.4/100 based on 25+ financial parameters.
Does Lupin Ltd pay dividends?
Lupin Ltd has a dividend yield of 0.72%. Past dividends don't guarantee future payments.
What is the ROE of Lupin Ltd?
Lupin Ltd has ROE of 28.68%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lupin Ltd?
Lupin Ltd has debt-to-equity of 0.29.
Is Lupin Ltd a good investment?
Bull Run gives Lupin Ltd a score of 83.4/100. This is not investment advice — consult a SEBI-registered advisor.